Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 23 for:    cancer | Studies received from 04/22/2016 to 04/22/2016
Previous Study | Return to List | Next Study

Fusion Guided Focal Laser Ablation of Prostate Cancer

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified April 18, 2017 by National Institutes of Health Clinical Center (CC)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) Identifier:
First received: April 22, 2016
Last updated: April 26, 2017
Last verified: April 18, 2017


Prostate cancer is the most common non-skin cancer in U.S. men. Treatments for early or less aggressive disease are limited. Researchers want to test a device that destroys cancerous tissue with laser energy. They want to see if using it with ultrasound is more comfortable than using it with magnetic resonance imaging (MRI).


To test a cooled laser applicator system to treat prostate cancer lesions. To see if ultrasound imaging is a practical and feasible treatment with laser ablation for focal prostate cancer treatment.


Men at least 18 years old with prostate cancer seen on MRI that has not spread in the body.


Participants will be screened with standard cancer care tests. These can include physical exam, lab tests, and MRI. For the MRI, they lie in a machine that takes pictures. Participants will have a prostate biopsy. Needle samples will be taken from 12 places in the prostate. This will be guided by MRI and ultrasound, which is obtained through a coil in the rectum.

Participants will stay at the clinic for 1 2 days. A cooling catheter (plastic tube) will be put in the bladder. Ultrasound will guide the laser applicator directly to the tumor.

The cooling catheter will be removed. A different catheter will be put in the urethra to keep the bladder emptied.

The next day, participants will have a physical exam and a PSA blood test.

Participants will have 6 follow-up visits over 3 years. At each visit, they will have a physical exam and lab tests. At some visits, they will also have an MRI or other scans and a prostate biopsy.

Condition Intervention
Prostate Cancer
Prostate Neoplasms
Device: 1.2.Laser Ablation Device

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Pilot Study of Fusion Guided Focal Laser Ablation of Prostate Cancer

Resource links provided by NLM:

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • To determine the feasibility of ultrasound (US) image-guided focal laser ablation of biopsy-confirmed and MR-visible, low-grade prostate tumor(s). [ Time Frame: duration of protocol ]

Secondary Outcome Measures:
  • To determine changes in imaging and biopsy characteristics after thermal ablation of localized prostate cancer. [ Time Frame: 3 years after treatment completed ]

Estimated Enrollment: 30
Study Start Date: April 15, 2016
Estimated Study Completion Date: January 1, 2019
Estimated Primary Completion Date: January 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
ultrasound image-guided focal laser ablation (FLA)
Device: 1.2.Laser Ablation Device
ultrasound image-guided focal laser ablation (FLA)

  Show Detailed Description


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
  • Patients must have clinically localized, low-volume, non-aggressive, low risk cancer: Organ confined clinical T1C or clinical T2a prostate cancer that is visualized on MR imaging.

    • T1c Tumor identified by needle biopsy (e.g., because of elevated PSA)
    • T2a Tumor confined within prostate and involves one-half of one lobe or less
  • Prostate cancer is diagnosed by transrectal ultrasound guided standard 12 core biopsy or MR image guided biopsy, or MR / US fusion guided biopsies. There may be up to 2 focal targets that are well-defined by imaging as verified by at least 2 radiologists
  • Gleason Score less than or equal to 7 (3+4) in 2 or fewer locations by fusion & standard 12 core biopsy
  • If 2 standard biopsy cores are positive, they must be from similar sextant location in the prostate as the MR or fusion-identified lesion that was biopsied and proven to be cancer. In other words, tumors must be visible on MR, with no clandestine tumor found by standard 12 core biopsy that could not be accounted for by visible positive MRI or fusion-defined targets.
  • Targeted tumors must be >5mm from urethra, rectal wall, or neurovascular bundle.
  • Must have had a prostate MRI performed at the NIH within 6 months prior to ablation.
  • No evidence of metastatic disease work per NCCN guidelines version 1.2016 Prostate Cancer
  • Bone scan indicated to r/o metastatic disease if [clinical T1 and PSA > 20 or T2 and PSA > 10, Gleason score>8, T3 or T4 tumors, symptomatic disease]
  • PSA < 15 ng/ml, or PSA density (PSA/prostate volume) < 0.15 ng/mL2 in patients with a PSA > 15 ng/mL
  • Men >18 years of age.
  • ECOG performance status less than or equal to 2 (Karnofsky >60%).
  • Patients must have normal organ and marrow function as defined below:

    • leukocytes >3,000/mcL
    • absolute neutrophil count >1,500/mcL
    • platelets >100,000/mcL
    • total bilirubin within normal institutional limits
    • AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal
    • creatinine within normal institutional limits


  • creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.

    • Preoperative clearance by NIH Department of Anesthesia and Surgical Services
    • Ability of subject to understand and the willingness to sign a written informed consent document.
  • Subject understands that this is an experimental treatment and that there are available standard treatment options. These options would include but not be limited to: active surveillance, external beam radiation and brachytherapy, androgen deprivation therapy, focal cryoablation, or prostatectomy.


  • Presence of 3 or more distinct MR visible lesions that is also positive on biopsy, or presence of multi-focal disease in 3 or more sextants, regardless of MRI visibility.
  • Presence of extra capsular, seminal vesical invasion or metastatic disease per NCCN guidelines. Bone scan indicated to rule out metastatic disease if [clinical T1 and PSA > 20 or T2 and PSA > 10] .
  • Patient unable to commit to follow up.
  • History of prior treatment for prostate cancer.
  • Acute urinary tract infection.
  • Patients with uncontrolled coagulopathies.
  • Altered mental status preventing consent or answering questions during conduct of the trial will be excluded for safety purposes.
  • Other serious illnesses according to the PI: involving the cardiac, respiratory, CNS, renal or hepatic organ systems, that would preclude study completion or increase risks of local therapies above an acceptable level.
  • Inability to undergo a contrast enhanced MRI per American College of Radiology and the Clinical Center, Department of Radiology guidelines.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02759744

Contact: Charisse Garcia, R.N. (301) 594-4511

United States, Maryland
National Institutes of Health Clinical Center Not yet recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010   
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
Principal Investigator: Bradford Wood, M.D. National Institutes of Health Clinical Center (CC)
  More Information

Additional Information:
Responsible Party: National Institutes of Health Clinical Center (CC) Identifier: NCT02759744     History of Changes
Other Study ID Numbers: 160098
Study First Received: April 22, 2016
Last Updated: April 26, 2017

Keywords provided by National Institutes of Health Clinical Center (CC):
Thermal Ablation
Localized Prostate Cancer
Thermal Damage
PSA Levels

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on April 27, 2017